Capital Analysts, LLC Amgen Inc Transaction History

Capital Analysts, LLC

  • $2.45 Billion
  • Q3 2024

A detailed history of Capital Analysts, LLC transactions in Amgen Inc stock. As of the latest transaction made, Capital Analysts, LLC holds 1,890 shares of AMGN stock, worth $495,614. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,890
Previous 1,857 1.78%
Holding current value
$495,614
Previous $580,000 4.83%
% of portfolio
0.02%
Previous 0.03%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$309.38 - $337.38 $10,209 - $11,133
33 Added 1.78%
1,890 $608,000
Q2 2024

Aug 14, 2024
BUY
$262.75 - $319.31 $37,047 - $45,022
141 Added 8.22%
1,857 $580,000
Q1 2024

May 14, 2024
BUY
$268.87 - $324.56 $3,764 - $4,543
14 Added 0.82%
1,716 $488,000
Q4 2023

Jan 30, 2024
SELL
$255.7 - $288.46 $4,091 - $4,615
-16 Reduced 0.93%
1,702 $490,000
Q3 2023

Nov 13, 2023
BUY
$218.65 - $271.46 $26,456 - $32,846
121 Added 7.58%
1,718 $462,000
Q2 2023

Aug 11, 2023
BUY
$214.27 - $253.37 $1,928 - $2,280
9 Added 0.57%
1,597 $355,000
Q1 2023

May 05, 2023
BUY
$225.79 - $275.2 $23,933 - $29,171
106 Added 7.15%
1,588 $383,000
Q4 2022

Feb 08, 2023
SELL
$229.03 - $291.01 $25,422 - $32,302
-111 Reduced 6.97%
1,482 $389,000
Q3 2022

Nov 14, 2022
BUY
$224.46 - $253.15 $4,713 - $5,316
21 Added 1.34%
1,593 $360,000
Q2 2022

Aug 12, 2022
BUY
$230.71 - $256.74 $922 - $1,026
4 Added 0.26%
1,572 $382,000
Q1 2022

May 12, 2022
SELL
$219.27 - $242.57 $10,086 - $11,158
-46 Reduced 2.85%
1,568 $379,000
Q4 2021

Feb 10, 2022
SELL
$198.88 - $227.6 $19,490 - $22,304
-98 Reduced 5.72%
1,614 $363,000
Q3 2021

Nov 04, 2021
BUY
$212.27 - $248.7 $30,991 - $36,310
146 Added 9.32%
1,712 $364,000
Q2 2021

Nov 15, 2021
SELL
$233.58 - $259.14 $126,600 - $140,453
-542 Reduced 25.71%
1,566 $381,000
Q2 2021

Aug 05, 2021
SELL
$233.58 - $259.14 $1.72 Million - $1.91 Million
-7,368 Reduced 77.75%
2,108 $513,000
Q1 2021

May 17, 2021
BUY
$221.91 - $258.6 $368,592 - $429,534
1,661 Added 21.25%
9,476 $2.36 Million
Q4 2020

Feb 16, 2021
BUY
$216.38 - $257.67 $93,908 - $111,828
434 Added 5.88%
7,815 $1.8 Million
Q3 2020

Nov 12, 2020
BUY
$234.65 - $260.95 $91,278 - $101,509
389 Added 5.56%
7,381 $1.88 Million
Q2 2020

Aug 07, 2020
SELL
$197.81 - $242.74 $46,287 - $56,801
-234 Reduced 3.24%
6,992 $1.65 Million
Q1 2020

May 08, 2020
SELL
$182.24 - $241.7 $55,583 - $73,718
-305 Reduced 4.05%
7,226 $1.47 Million
Q4 2019

Feb 12, 2020
BUY
$189.21 - $243.2 $42,383 - $54,476
224 Added 3.07%
7,531 $1.82 Million
Q3 2019

Nov 12, 2019
BUY
$174.11 - $208.62 $21,937 - $26,286
126 Added 1.75%
7,307 $1.41 Million
Q2 2019

Aug 13, 2019
SELL
$166.7 - $195.41 $73,348 - $85,980
-440 Reduced 5.77%
7,181 $1.32 Million
Q1 2019

May 13, 2019
SELL
$180.87 - $203.88 $47,568 - $53,620
-263 Reduced 3.34%
7,621 $1.45 Million
Q4 2018

Feb 13, 2019
SELL
$178.4 - $208.25 $6,779 - $7,913
-38 Reduced 0.48%
7,884 $1.54 Million
Q3 2018

Nov 07, 2018
BUY
$185.29 - $208.89 $24,272 - $27,364
131 Added 1.68%
7,922 $0
Q2 2018

Aug 03, 2018
BUY
$166.05 - $186.51 $24,077 - $27,043
145 Added 1.9%
7,791 $0
Q1 2018

May 14, 2018
BUY
$169.43 - $198.0 $112,840 - $131,868
666 Added 9.54%
7,646 $1.3 Million
Q4 2017

Feb 14, 2018
BUY
$168.79 - $188.59 $1 Million - $1.12 Million
5,930 Added 564.76%
6,980 $1.21 Million
Q4 2017

Feb 12, 2018
SELL
$168.79 - $188.59 $948,599 - $1.06 Million
-5,620 Reduced 84.26%
1,050 $137,000
Q3 2017

Nov 06, 2017
BUY
$167.29 - $191.0 $1.12 Million - $1.27 Million
6,670
6,670 $1.24 Million

Others Institutions Holding AMGN

# of Institutions
3,119
Shares Held
407M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $140B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Capital Analysts, LLC Portfolio

Follow Capital Analysts, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email